BIO-TECHNE Corp (TECH) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $26.70M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $38.40M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $4.03M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $26.70M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $26.70M |
| Deferred revenue · latest quarter (USD) | $38.40M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $36.07M + $2.33M ≈ $38.40M |
| Other obligations · due within 1 year (USD) | $4.03M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $4.03M |
| Other obligations · due after 1 year (USD) | $19.02M | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $21.34M − $2.33M ≈ $19.02M |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | (m) | |
| Borrowing debt | (m) | Long-term Debt, Current Maturities |
| Amounts owed to suppliers | 26.70M USD | Accounts Payable, Current |
| Total deferred revenue | 38.40M USD | Contract with Customer, Liability · Contract with Customer, Liability, Current · Deferred Revenue, Current |
| Deferred revenue due within one year | 36.07M USD | Contract with Customer, Liability, Current · Deferred Revenue, Current |
| Deferred revenue due after one year | 2.33M USD | Contract with Customer, Liability · Contract with Customer, Liability, Current · Deferred Revenue, Current |
| Reported other obligations due within one year | 4.03M USD | Other Liabilities, Current |
| Reported other noncurrent obligations | 21.34M USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | 2.33M USD | Contract with Customer, Liability · Contract with Customer, Liability, Current · Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $4.03M
- Other obligations · due after 1 year (USD)
- $19.02M
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Income taxes payable | $3.59M |
| Operating lease obligations | $89.09M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $26.70M | $38.40M | $4.03M | $19.02M | (m) | (m) | $36.07M | $2.33M | $21.34M | $2.33M |
| 2026-03-31 | (m) | $23.49M | $40.70M | $2.09M | $19.40M | (m) | (m) | $38.43M | $2.27M | $21.67M | $2.27M |
| 2025-12-31 | (m) | $26.27M | $33.00M | $1.58M | $21.11M | (m) | (m) | $31.03M | $1.97M | $23.08M | $1.97M |
| 2025-09-30 | (m) | $30.16M | $32.70M | $4.55M | $21.56M | (m) | (m) | $30.45M | $2.25M | $23.81M | $2.25M |
| 2025-06-30 | (m) | $25.31M | $35.30M | $1.65M | $24.35M | (m) | (m) | $32.57M | $2.73M | $27.08M | $2.73M |
| 2025-03-31 | (m) | $31.64M | $35.60M | $1.81M | $12.32M | (m) | (m) | $32.27M | $3.33M | $15.66M | $3.33M |
| 2024-12-31 | (m) | $33.12M | $30.40M | $2.63M | $8.65M | (m) | (m) | $27.71M | $2.69M | $11.34M | $2.69M |
| 2024-09-30 | (m) | $31.56M | $29.20M | $4.27M | $17.20M | (m) | (m) | $26.61M | $2.59M | $19.79M | $2.59M |
| 2024-06-30 | (m) | $37.97M | $30.20M | $2.15M | $10.89M | (m) | (m) | $27.93M | $2.27M | $13.16M | $2.27M |
| 2024-03-31 | (m) | $28.89M | $32.00M | $2.95M | $9.66M | (m) | (m) | $30.11M | $1.89M | $11.56M | $1.89M |
| 2023-12-31 | (m) | $31.51M | $30.10M | $4.22M | $15.69M | (m) | (m) | $28.43M | $1.67M | $17.36M | $1.67M |
| 2023-09-30 | (m) | $28.08M | $25.80M | $4.44M | $8.11M | (m) | (m) | $24.52M | $1.28M | $9.39M | $1.28M |
| 2023-06-30 | (m) | $25.68M | $24.60M | $1.41M | $9.39M | (m) | (m) | $23.07M | $1.53M | $10.92M | $1.53M |
| 2023-03-31 | (m) | $27.12M | $26.50M | $865.00K | $9.35M | (m) | (m) | $24.88M | $1.62M | $10.97M | $1.62M |
| 2022-12-31 | (m) | $24.10M | $23.50M | $1.32M | $9.65M | (m) | (m) | $21.81M | $1.69M | $11.34M | $1.69M |
| 2022-09-30 | (m) | $30.48M | $24.00M | $1.96M | $9.56M | (m) | (m) | $22.06M | $1.94M | $11.50M | $1.94M |
| 2022-06-30 | (m) | $33.87M | $25.50M | $1.24M | $10.14M | (m) | (m) | $23.41M | $2.09M | $12.24M | $2.09M |
| 2022-03-31 | (m) | $30.86M | $25.10M | $3.08M | $10.78M | (m) | (m) | $23.11M | $1.99M | $12.77M | $1.99M |
| 2021-12-31 | (m) | $26.76M | $20.80M | $5.47M | $10.03M | (m) | (m) | $19.08M | $1.72M | $11.75M | $1.72M |
| 2021-09-30 | (m) | $25.62M | $20.10M | $3.61M | $19.07M | (m) | (m) | $19.12M | $979.00K | $20.05M | $979.00K |
| 2021-06-30 | (m) | $29.38M | $20.00M | $3.89M | $23.46M | (m) | (m) | $19.00M | $1.00M | $24.46M | $1.00M |
| 2021-03-31 | (m) | $25.84M | $19.70M | $2.58M | $22.83M | (m) | (m) | $18.71M | $986.00K | $23.81M | $986.00K |
| 2020-12-31 | (m) | $24.25M | $14.40M | $3.17M | $24.61M | (m) | (m) | $13.22M | $1.18M | $25.80M | $1.18M |
| 2020-09-30 | (m) | $27.19M | $13.40M | (m) | $29.87M | (m) | (m) | $13.29M | $115.00K | $29.98M | $115.00K |
| 2020-06-30 | (m) | $23.09M | $14.20M | (m) | $25.80M | (m) | (m) | $13.05M | $1.15M | $26.95M | $1.15M |
| 2020-03-31 | (m) | $19.73M | $14.80M | (m) | $26.81M | (m) | (m) | $13.56M | $1.24M | $28.05M | $1.24M |
| 2019-12-31 | (m) | $19.09M | $13.20M | (m) | $19.40M | (m) | (m) | $11.89M | $1.31M | $20.71M | $1.31M |
| 2019-09-30 | (m) | $14.11M | $10.50M | (m) | $21.06M | (m) | (m) | $9.11M | $1.39M | $22.45M | $1.39M |
| 2019-06-30 | (m) | $16.21M | $10.40M | (m) | $23.91M | (m) | (m) | $9.08M | $1.32M | $25.22M | $1.32M |
| 2019-03-31 | (m) | $14.90M | $11.50M | (m) | $18.11M | (m) | (m) | $10.11M | $1.39M | $19.50M | $1.39M |
| 2018-12-31 | (m) | $16.01M | $9.70M | (m) | $16.69M | (m) | (m) | $8.40M | $1.30M | $17.99M | $1.30M |
| 2018-09-30 | (m) | $18.26M | $10.60M | (m) | $7.83M | (m) | (m) | $8.76M | $1.84M | $9.67M | $1.84M |
| 2018-06-30 | (m) | $18.45M | (m) | (m) | (m) | (m) | (m) | $7.07M | (m) | $9.34M | (m) |
| 2018-03-31 | (m) | $14.53M | (m) | (m) | (m) | (m) | (m) | $7.84M | (m) | $9.14M | (m) |
| 2017-12-31 | (m) | $11.32M | (m) | (m) | (m) | (m) | (m) | $6.02M | (m) | $9.32M | (m) |
| 2017-09-30 | (m) | $15.08M | (m) | (m) | (m) | (m) | (m) | $5.37M | (m) | $6.25M | (m) |
| 2017-06-30 | (m) | $16.86M | (m) | (m) | (m) | (m) | (m) | $5.97M | (m) | $5.40M | (m) |
| 2017-03-31 | (m) | $12.03M | (m) | (m) | (m) | (m) | (m) | $6.07M | (m) | $4.40M | (m) |
| 2016-12-31 | (m) | $12.91M | (m) | (m) | (m) | (m) | (m) | $4.85M | (m) | $3.63M | (m) |
| 2016-09-30 | (m) | $14.18M | (m) | (m) | (m) | (m) | (m) | $4.48M | (m) | $3.65M | (m) |
| 2016-06-30 | (m) | $20.65M | (m) | (m) | (m) | (m) | (m) | $4.72M | (m) | $3.32M | (m) |
| 2016-03-31 | (m) | $13.52M | (m) | (m) | (m) | (m) | (m) | $5.22M | (m) | $3.16M | (m) |
| 2015-12-31 | (m) | $10.43M | (m) | (m) | (m) | (m) | (m) | $3.14M | (m) | $3.22M | (m) |
| 2015-09-30 | (m) | $13.18M | (m) | (m) | (m) | (m) | (m) | $3.84M | (m) | $3.15M | (m) |
| 2015-06-30 | (m) | $13.44M | (m) | (m) | (m) | (m) | (m) | $3.38M | (m) | $3.20M | (m) |
| 2015-03-31 | (m) | $13.51M | (m) | (m) | (m) | (m) | (m) | $3.49M | (m) | $2.14M | (m) |
| 2014-12-31 | (m) | $13.13M | (m) | (m) | (m) | (m) | (m) | $2.81M | (m) | $1.90M | (m) |
| 2014-09-30 | (m) | $13.57M | (m) | (m) | (m) | (m) | (m) | $2.54M | (m) | $708.00K | (m) |
| 2014-06-30 | (m) | $9.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $8.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $7.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $6.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $6.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $6.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $6.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $6.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $6.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $6.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $5.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $5.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $5.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $5.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $3.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | $4.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | $5.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |